The authorities have begun rolling out a new all-oral treatment for drug-resistant tuberculosis, significantly reducing treatment time and improving patient outcomes. The regimen, known as BPaL/M, cuts the standard treatment period from 18 months to just six.  It also has the potential to cut hospital costs by up to 60%. It includes the drugs bedaquiline,...

Unlock this article with Premium. To access all premium content, contact us at [email protected]
Already a member? Log in here